Clozapine Use and Relapses of Substance Use Disorder Among Patients With Co-occurring Schizophrenia and Substance Use Disorders
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous correlational research with schizophrenic patients has suggested that the second-generation antipsychotic medication clozapine helps to induce remissions of substance use disorder in patients with co-occurring psychosis and substance abuse. This research, however, could be biased by selection factors. Studying patients who are currently in substance abuse remission could control for level of motivation to stop using substances and other methodological confounds. METHODS: To test whether clozapine was associated with prevention of substance abuse relapses, we examined patients with schizophrenia or schizoaffective disorder who were in their first 6-month remission of substance use disorder during a prospective 10-year follow-up study. All patients received yearly multimodal assessments of substance use. Antipsychotic medications were prescribed by community doctors as part of usual clinical care. RESULTS: Patients using clozapine at the first 6-month period of substance abuse remission (n = 25) were much less likely to relapse over the next year compared with those on other antipsychotic medications (n = 70): 8.0% vs 40.0%, chi(2) = 8.73 (df = 1), P = .003. Although medication assignment was not randomized, several potential confounders were similar between the groups. CONCLUSION: Clozapine should be considered for the treatment of patients with schizophrenia and co-occurring substance use disorder to prevent relapses to substance abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.31 · Cited by 589 · cited 1×
“Comorbid substance use disorder (termed ‘‘substance abuse’’ in this report) is common in patients with schizophrenia(1) and is associated with a variety of serious adverse consequences, such as relapse of mental illness,(2,3) hospitalization,(4,5) violence,(6) decreased functioning,(7) homelessness,(8) and serious inf…”
BackgroundDual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes
DIXON, L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00161-3 · Cited by 472
Drake, R. E., Mueser, K. T., Brunette, M. F., & McHugo, G. J. (2004) · Psychiatric Rehabilitation Journal · doi:10.2975/27.2004.360.374 · Cited by 459
Self-citationSubstance use: a powerful predictor of relapse in schizophrenia
Swofford, C. D., Kasckow, J. W., Scheller-Gilkey, G., & Inderbitzin, L. B. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00068-2 · Cited by 247
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationBarnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“40%), but there was no difference in improvement in psychiatric symptoms (Brunette et al., 2006) (III).”
BackgroundThe link between schizophrenia and substance use disorder: A unifying hypothesis
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.016 · Cited by 281
Self-citationTorrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663296 · Cited by 122
Metadata
- Authors
- Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-12
- Volume
- 32
- Issue
- 4
- Pages
- 637-643
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2128601077
- Cited by
- 142
- References
- 5
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine Use and Relapses of Substance Use Disorder Among Patients With Co-occurring Schizophrenia and Substance Use Disorders. https://app.cochat.ai/papers/10.1093/schbul/sbl003
- The paper
- Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2005). Clozapine Use and Relapses of Substance Use Disorder Among Patients With Co-occurring Schizophrenia and Substance Use Disorders. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbl003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.